$1.6bn Agila injects strengths into Mylan

Mylan has snapped up Strides Arcolab's injectables arm, Agila Specialties, for $1.6 billion, plus $250 million in additional conditional payments, a transaction, which though seen as expensive, is expected to fast-track Mylan's approach towards becoming a top-three global player in the injectables space.

Mylan has snapped up Strides Arcolab's injectables arm, Agila Specialties, for $1.6 billion, plus $250 million in additional conditional payments, a transaction, which though seen as expensive, is expected to fast-track Mylan's approach towards becoming a top-three global player in the injectables space.

Sample this: Mylan-Agila combined will have more than 700 marketed injectables products and a global pipeline of over 350 injectables...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Anticancer

More from Therapeutic Category

BMS’s Reblozyl Misses Primary Endpoint In Myelofibrosis Anemia

 

The drugmaker announced topline results from the Phase III INDEPENDENCE trial, which did meet key secondary endpoints.

Insmed’s New R&D Site Focused On ‘Synthetic Rescue’

 

A new small-molecule approach to turning on beneficial genes to counteract disease-causing mutations is being pioneered by Insmed’s UK-based scientists.

AI-First, Big Pharma, Chinese Firms In Race - What’s Ahead For PRMT5 Inhibitors

 
• By 

As AI-driven firms including Insilico, big pharmas J&J, Amgen, GSK and AstraZeneca and Chinese and Indian firms like BeOne and Dr. Reddy’s advance PRMT5 inhibitor candidates, what’s driving interest, what could lead to the first global approval and what are the challenges ahead?